Personalized SpO2 Target for Critical Illness

(EXPRESS Trial)

This trial tests a new method for setting oxygen levels in critically ill patients on ventilators. It seeks to determine if a personalized approach to oxygen targets (the optimal oxygen level for each individual) can enhance recovery. Patients will either receive a tailored oxygen level based on their specific needs or the usual care without personalization. Suitable candidates for this trial include those in an intensive care unit using a ventilator for breathing assistance. As an unphased trial, this study provides an opportunity to contribute to innovative research that could improve personalized care for future patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that personalized oxygen levels might be safe for seriously ill adults. In earlier studies, patients who received customized oxygen targets experienced better health outcomes. A computer program predicts the best oxygen levels for each person, and trials have tested this method, showing promise in lowering death rates.

Safety data from these trials suggest that adjusting oxygen levels based on individual needs does not cause harm. For instance, patients who maintained oxygen levels between 94% and 98% during most of their ICU stay had lower death rates in the hospital. These findings indicate that personalized oxygen targets are well-tolerated by patients.

Researchers are excited about the Personalized SpO2 Target approach because it tailors oxygen levels to each critically ill patient’s unique needs. Unlike standard care, which uses a one-size-fits-all approach to oxygen therapy, this method employs a statistical model to determine the optimal oxygen saturation for individual patients. By personalizing SpO2 targets, the treatment aims to improve patient outcomes by providing more precise and effective care, potentially reducing complications associated with improper oxygen levels.

Research has shown that setting personalized oxygen levels for critically ill patients can improve their outcomes. In this trial, participants in the Personalized SpO2 Target Group will have their oxygen levels adjusted based on a statistical model that considers their baseline characteristics. Studies using advanced computer techniques suggest that these customized targets might lower death rates. Specifically, one study predicted a 6.4% drop in deaths within 28 days when patients received oxygen adjusted to their specific needs. Although no overall difference was found between high and low oxygen levels, recent research indicates that personalized targets hold promise. These targets, tailored to each patient’s condition, could lead to better survival rates and improved care quality.¹²³⁴⁵